Clinical trial
Long-Term Extension Study of MP-214 in Patients With Schizophrenia
NCT01626872 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-Term Extension Study of MP-214 in Patients With Schizophrenia
- Lead sponsor
- Tanabe Pharma Corporation
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2012
- Completion date
- October 31, 2016
- Enrollment
- 254 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.